We claim:

1. A monoclonal antibody (mAb) that binds and neutralizes human Hepatocyte Growth Factor (HGF).

2. The mAb of claim 1 which is chimeric.

3. The mAb of claim 1 which is humanized.

4. The mAb of claim 1 which is human.

5. The mAb of claim 1 which inhibits binding of HGF to cMet by at least 50%.

6. The mAb of claim 1 which inhibits HGF-induced scattering of Madin-Darby canine kidney cells.

7. The mAb of claim 1 which inhibits HGF-induced proliferation of HUVEC cells.

8. The mAb of claim 1 which inhibits HGF-induced angiogenesis.

9. The mAb of claim 1 which neutralizes all biological activities of HGF.

10. The mAb of claim 1 which inhibits growth of a human tumor xenograft in a mouse when used as a single agent.

11. The mAb of claim 1 which is a Fab or $F(ab')_2$ fragment or single-chain antibody.

12. An anti-HGF mAb selected from the group of L1H4, L2C7 and L2G7.

13. A chimeric or humanized L2G7 mAb.

14. A cell line producing a mAb of claim 1.

15. A cell line producing a mAb of claim 13.

16. A pharmaceutical composition comprising a mAb of claim 1.

17. A pharmaceutical composition comprising a mAb of claim 13..

18. A method of treating cancer in a patient comprising administering to the patient a pharmaceutical composition comprising a neutralizing anti-HGF mAb.

19. A method of claim 18 wherein said cancer is glioblastoma.

20. The method of claim 18 wherein said mAb is a chimeric or humanized L2G7 mAb.